A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

Radical prostatectomy is a common surgical procedure performed to treat prostate cancer. Patient-reported outcomes after surgery include urinary incontinence, erectile dysfunction, decreased quality ...

Thanks to early detection and aggressive treatment for prostate cancer, 97 percent of all men diagnosed with the disease will survive at least 5 years and nearly 80 percent will survive at least a ...

FDA-authorized AI tools have the potential to help patients with prostate cancer get clearer answers instead of waiting weeks for genomic test results. FDA-authorized artificial intelligence (AI) ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved piflufolastat (18F) (Pylclari, Curium Pharma) as a diagnostic tool for people with suspected or known prostate cancer. It ...

Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC) ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...

When U.S. Sen. Bob Casey of Pennsylvania courageously shared his prostate cancer diagnosis and surgery earlier this year, he credited the support of his family and his exceptional medical care for his ...